Novo Nordisk A S (NVO)
| Sector: | Health Care |
| Super Investor Stats: | |
| Ownership count: | 4 |
| Ownership rank: | 127 |
| % of all portfolios: | 0.065% |
| Hold Price * : | $119.07 |
| History | Portfolio Manager | Activity ▼ | Share change | % change to portfolio | |
| Q2 2024 | |||||
| ≡ | Lee Ainslie - Maverick Capital | Add 272.87% | 5,744 | 0.01 | |
| Q1 2024 | |||||
| ≡ | Lee Ainslie - Maverick Capital | Buy | 2,105 | 0.01 | |
| Q4 2023 | |||||
| ≡ | Polen Capital Management | Add 0.66% | 52,189 | 0.01 | |
| Q3 2023 | |||||
| ≡ | Polen Capital Management | Buy | 7,906,255 | 1.89 | |
| Q2 2023 | |||||
| ≡ | Chase Coleman - Tiger Global Management | Buy | 1,269,000 | 0.86 | |
| Q3 2022 | |||||
| ≡ | Lee Ainslie - Maverick Capital | Buy | 4,950 | 0.01 | |
| Q3 2020 | |||||
| ≡ | Francois Rochon - Giverny Capital | Buy | 12,400 | 0.04 | |
| ≡ | Lee Ainslie - Maverick Capital | Buy | 17,866 | 0.01 | |
| Q4 2019 | |||||
| ≡ | Polen Capital Management | Add 71.82% | 99,320 | 0.01 | |
| Q3 2019 | |||||
| ≡ | Polen Capital Management | Add 16.52% | 19,612 | 0.00 | |
| Q2 2019 | |||||
| ≡ | Polen Capital Management | Add 29.13% | 26,776 | 0.00 | |
| Q2 2012 | |||||
| ≡ | Thomas Gayner - Markel Group | Add 0.84% | 19,000 | 0.01 | |
| Q1 2010 | |||||
| ≡ | Thomas Gayner - Markel Group | Add 39.04% | 650,000 | 0.31 | |
| Q4 2009 | |||||
| ≡ | Thomas Gayner - Markel Group | Buy | 1,665,000 | 0.75 | |
* "Hold Price" is the last known price at which an investor still held a security. It is the closing price of the security as of the portfolio date (quarter end). This value is only provided when a security is owned by at least two investors. In the case of reporting dates being different, a weighted average price is calculated.